Clinical Trial Update: Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating neoadjuvant/adjuvant GVAX versus mKRASvax given with anti-PD-1 and anti-CD137 in surgically resectable pancreatic cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Anti-PD-1 antibody
• GVAX
• anti-CD137 antibody
• mKRASvax

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING